IPT recently sat down with Michael Avraam to talk about what challenges and obstacles companies may face when working with high potency API processes. Michael looked at containment and product handling strategies that must be adopted to meet safety, quality and compliance goals. He also explored what approaches might best serve manufacturers to mitigate the risk and cost of manufacturing HPAPIs.
Find out more in his interview here.
